

April 1, 2019



SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

JERSEY CITY, N.J., April 1, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor conferences:

- The H.C. Wainwright Global Life Sciences Conference at the Grosvenor House A JW Marriott Hotel in London on Monday, April 8, 2019 at 4:50 p.m. GMT.
- The 18th Annual Needham Healthcare Conference at the Westin Grand Central Hotel in New York City on Wednesday, April 10, 2019 at 10:40 a.m. ET.

Live webcasts of the presentations will be available on the Investors section of the Company's website: www.scynexis.com. Replays of the presentations will be available approximately two hours after each event and will be available for two weeks following each presentation.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by *Candida* and *Aspergillus* species. For more information, visit www.scynexis.com.

CONTACT:

Investor Relations

Heather Savelle
Argot Partners
Tel: 212-600-1902
heather@argotpartners.com

Media Relations

George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093
george@macbiocom.com

View original content: <http://www.prnewswire.com/news-releases/scynexis-inc-to-present->

[at-upcoming-investor-conferences-300821279.html](#)

SOURCE SCYNEXIS, Inc.